The Global Life Sciences Team is continually trying to align itself with shifting trends in the industry. We have seen momentous change over the past couple of years. Government run health care, cross border importation, and decreased patent years have triggered a significant amount of industry consolidation. There is an expectation of a capacity shortage of generics by 2012 given the approximately $120B of patent expiration, and the grey factor; 24% of population will be over 60 by 2012. Innovation has softened the regulatory sting of the FDA making ASTM E2500 methodologies (eliminates duplication of testing) and Process Analytical Technology (PAT) more viable. Disease profiles are becoming demographically specific with fewer blockbusters and smaller batches on the horizon.
A recently posted SupplyChainBrain video below highlights Janice Abel, Principal Analyst at ARC Advisory Group who does an exceptional job at summarizing some of these recent events and key trends in the Pharmaceutical Industry. Some of the central points addressed include:
- Sales and Automation growth
- What is the industry doing to improve its portfolio?
- Merger & Acquisitions and related capital requirements
- Capacity and efficiency challenges of manufacturers
- Risk-based methodologies
Janice's final comments on technology investment having to show business merit, underscores much of what we advocate as we strive to present value-based solutions to our customer base. Enjoy the video!
